Nasdaq

Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis

(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
Business Insider

Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting

WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...
Business Insider

Radius Health Initiates Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture

Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...
Mena FN

Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS (abaloparatide) Injection at ENDO 2019 Annual Meeting Nasdaq:RDUS

(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis ...
Monthly Prescribing Reference

Tymlos Approved for Men With Osteoporosis at High Risk for Fracture

Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...